Full Description
Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer's disease, Parkinson's disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.
This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.
Contents
Preface: What Do You Mean By "Translational Research”? An Enquiry through Animal and Translational Models for CNS Drug Discovery: Neurological Disorders
Robert A McArthur and Franco Borsini
1. A. Jackie Hunter. Animal and Translational Models of Neurological Disorders: An Industrial Perspective
2. Lon S Schneider. Issues in Design and Conduct of Clinical Trials for Cognitive-Enhancing Drugs
3. C. Shilyansky et al. Molecular And Cellular Mechanisms Of Learning Disabilities: A Focus On Neurofibromatosis Type I
4. M. Lindner et al. Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease
5. K. Merchant et al. Animal Models of Parkinson's Disease to Aid Drug Discovery and Development
6. T. Wagner et al. Huntington Disease
7. J. Montes. Translational Research in ALS
8. H. Klitgaard. Animal and Translational Models of the Epilepsies
Epilogue:
Translational Models for the 21st century: Reminiscence, Reflections and Some Recommendations
Paul Willner, Franco Borsini, and Robert A McArthur
